IRCT20200407046981N6招募中未知
Randomized, single-dose, crossover comparative bioequivalence study of the Gefitinib 250 mg tablets produced by Kimia pharmaceutical Co versus Iressa® (AstraZeneca company) in 30 healthy males under fasting conditions
Kimia pharmaceutical Co0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- Male
入选标准
- •The weight limit for each volunteer is between 60 and 100 kg.
- •All volunteers must be non-smokers.
- •They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Erlotinib or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two week before dosing.
研究者
相似试验
招募中
不适用
Study of absorption and elimination rate of Erlotinib 150 mg tablets in comparison with standard tablet of Erlotinib (Tarceva).IRCT20200407046981N7Kimia pharmaceutical Co30
已完成
不适用
Bioequivalence study of Ondansetron 4 mg film-coated tablet in 24 healthy male under fasting conditionsIRCT20180620040164N2Aburaihan pharmaceutical co.24
招募中
不适用
Study of absorption and elimination rate of Imatinib 100 mg capsules in comparison with standard tablet of Imatinib (Imatinib).IRCT20200407046981N4Kimia pharmaceutical Co18
已完成
不适用
Bioequivalence study of Linagliptin 5 mg tablets in 24 healthy male under fasting conditionsIRCT20180620040164N4Alhavi pharmaceutical co.24
尚未招募
不适用
Bioequivalence study of Teriflunomide 14 mg tablets produced by Zahravi Pharmaceutical Co. versus Aubagio® tablets of Sanofi Genzyme Co. in 14 healthy male under fasting conditionsImmunomodulatory drug for the treatment of Multiple Sclerosis (MS).IRCT20200407046981N1Zahravi pharmaceutical company14